Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 2
2002 1
2003 1
2007 1
2009 1
2010 1
2011 2
2012 4
2013 5
2014 4
2015 5
2016 4
2017 2
2018 5
2019 3
2020 3
2021 4
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Among authors: lerchenmuller c. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. Heinemann V, et al. Among authors: lerchenmuller c. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6. Br J Cancer. 2021. PMID: 33154570 Free PMC article. Clinical Trial.
Restoration of Cardiomyogenesis in Aged Mouse Hearts by Voluntary Exercise.
Lerchenmüller C, Vujic A, Mittag S, Wang A, Rabolli CP, Heß C, Betge F, Rangrez AY, Chaklader M, Guillermier C, Gyngard F, Roh JD, Li H, Steinhauser ML, Frey N, Rothermel B, Dieterich C, Rosenzweig A, Lee RT. Lerchenmüller C, et al. Circulation. 2022 Aug 2;146(5):412-426. doi: 10.1161/CIRCULATIONAHA.121.057276. Epub 2022 Jul 6. Circulation. 2022. PMID: 35862076 Free PMC article.
Mechanisms of exercise-induced cardiac growth.
Lerchenmüller C, Rosenzweig A. Lerchenmüller C, et al. Drug Discov Today. 2014 Jul;19(7):1003-9. doi: 10.1016/j.drudis.2014.03.010. Epub 2014 Mar 15. Drug Discov Today. 2014. PMID: 24637046 Review.
CITED4 Protects Against Adverse Remodeling in Response to Physiological and Pathological Stress.
Lerchenmüller C, Rabolli CP, Yeri A, Kitchen R, Salvador AM, Liu LX, Ziegler O, Danielson K, Platt C, Shah R, Damilano F, Kundu P, Riechert E, Katus HA, Saffitz JE, Keshishian H, Carr SA, Bezzerides VJ, Das S, Rosenzweig A. Lerchenmüller C, et al. Circ Res. 2020 Aug 14;127(5):631-646. doi: 10.1161/CIRCRESAHA.119.315881. Epub 2020 May 18. Circ Res. 2020. PMID: 32418505 Free PMC article.
miR-222 inhibits pathological cardiac hypertrophy and heart failure.
Liu X, Li H, Hastings MH, Xiao C, Damilano F, Platt C, Lerchenmüller C, Zhu H, Wei XP, Yeri A, Most P, Rosenzweig A. Liu X, et al. Among authors: lerchenmuller c. Cardiovasc Res. 2024 Mar 14;120(3):262-272. doi: 10.1093/cvr/cvad184. Cardiovasc Res. 2024. PMID: 38084908
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: lerchenmuller c. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
Intrinsic and Extrinsic Contributors to the Cardiac Benefits of Exercise.
Hastings MH, Castro C, Freeman R, Abdul Kadir A, Lerchenmüller C, Li H, Rhee J, Roh JD, Roh K, Singh AP, Wu C, Xia P, Zhou Q, Xiao J, Rosenzweig A. Hastings MH, et al. Among authors: lerchenmuller c. JACC Basic Transl Sci. 2023 Oct 18;9(4):535-552. doi: 10.1016/j.jacbts.2023.07.011. eCollection 2024 Apr. JACC Basic Transl Sci. 2023. PMID: 38680954 Free PMC article. Review.
51 results